EUVIMEDEUVIMED entdecken
Crossref

Concepts in Phase 1 Radiopharmaceutical Therapy Trial Designs: Lessons from the SNMMI Dose Optimization in Radiopharmaceutical Therapy Development Workshop

Michael J Morris, Thomas A Hope, Oliver Sartor

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.125.270792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Michael J Morris und 2 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Clinical Trials, Phase I as Topic, Nuclear Medicine, Research Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiopharmaceuticals represent a promising new frontier in cancer therapy. In the United States, cancer is the second leading cause of death. There is an urgent need to develop new therapies to meet this challenge, especially for those patients with advanced and refractory disease. The Society of Nuclear Medicine and Molecular Imaging and Food and Drug Administration convened a "Dose Optimization of Radiopharmaceutical Therapy Developmental Workshop" on May 6 and 7, 2024. Herein, we briefly summarize the highlights from that meeting from the perspective of the stakeholders involved, including multiple representatives from academia, industry, and the Food and Drug Administration. For patients with advanced treatment-refractory solid tumors, the greatest health-related risk is their cancer, rather than long-term toxicity from radiopharmaceutical therapies. In these patients, concerns about long-term nephrotoxicity, marrow toxicity, or the development of second malignancies are of lesser importance given that there is little or no long-term probability of survival. Phase 1 studies that explore dose and schedule are crucial because they set the stage for larger studies that potentially inform regulatory approval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsClinical Trials, Phase I as TopicNuclear MedicineResearch DesignHumansNeoplasms

Stichwörter der Autor:innen

FDASNMMIdosimetryphase 1radiopharmaceuticals

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; and.
  • East Jefferson Hospital and LCMC Health Care, and Departments of Medicine and Urology, Tulane University, New Orleans, Louisiana osartor@tulane.edu.

Zitieren

APA

Morris, M. J., Hope, T. A., & Sartor, O. (2026). Concepts in Phase 1 Radiopharmaceutical Therapy Trial Designs: Lessons from the SNMMI Dose Optimization in Radiopharmaceutical Therapy Development Workshop. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270792

Vancouver

Morris MJ, Hope TA, Sartor O. Concepts in Phase 1 Radiopharmaceutical Therapy Trial Designs: Lessons from the SNMMI Dose Optimization in Radiopharmaceutical Therapy Development Workshop. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.270792

BibTeX
@article{Morris2026,
  author = {Morris, Michael J and Hope, Thomas A and Sartor, Oliver},
  title = {Concepts in Phase 1 Radiopharmaceutical Therapy Trial Designs: Lessons from the SNMMI Dose Optimization in Radiopharmaceutical Therapy Development Workshop},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.125.270792}
}
Kostenlos starten →